{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-252990","form_type":"8-K","ticker":null,"cik":"0001661460","company_name":"Poseida Therapeutics, Inc.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.980065+00:00","generated_at":"2026-06-10T02:29:21.365492+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Poseida announces CEO transition; Kristin Yarema to become CEO, Mark Gergen to become Executive Chairman","bullets":["Kristin Yarema, currently President, Cell Therapy, appointed President and CEO effective January 1, 2024.","Mark Gergen, current President and CEO, will become Executive Chairman of the Board on the same date.","Amended employment agreements to be entered with Dr. Yarema and Mr. Gergen prior to effective date.","No material transactions or family relationships disclosed between Dr. Yarema and the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-252990","json":"https://secwatch.observer/filing/0001193125-23-252990.json","markdown":"https://secwatch.observer/filing/0001193125-23-252990.md","text":"https://secwatch.observer/filing/0001193125-23-252990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661460/000119312523252990/0001193125-23-252990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661460/000119312523252990/d472927d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:29:21.365492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9445430815","claim":"Mark Gergen was appointed as Executive Chairman at Poseida Therapeutics, Inc..","evidence_excerpt":"The Board also appointed Mark Gergen, the Company’s current President and Chief Executive Officer, as Executive Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312523252990/0001193125-23-252990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"b044c7af4f","claim":"Kristin Yarema was appointed as President and Chief Executive Officer at Poseida Therapeutics, Inc..","evidence_excerpt":"approved a leadership transition appointing Kristin Yarema, Ph.D., as President and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661460/000119312523252990/0001193125-23-252990-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}